Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schram

Showing results (41-50 of 186) with videos related to

Pageof 19
Sort By:
JCO Precision Oncology|March 21, 2025
Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase InhibitorsMara Rao, Madeline Merrill, Megan Troxel, et al.
Disability and Health Journal|June 10, 2024
Systemic barriers hinder person-centered home and community based services (HCBS): Perspectives of service users and professionalsNiveda Tennety, Bridgette M Schram, Jacqueline Kish, et al.
British Journal of Haematology|November 6, 2015
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 yearsAlison M Schram, Paige Comstock, Meghan Campo, et al.
American Journal of Clinical Pathology|July 17, 2023
BRAF testing modalities in histiocytic disorders: Comparative analysis and proposed testing algorithmAldo A Acosta-Medina, Jithma P Abeykoon, Ronald S Go, et al.
British Journal of Cancer|November 15, 2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursAlison M Schram, Leena Gandhi, Monica M Mita, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
ESMO Open|February 22, 2025
A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumorsA M Schram, V Boni, A A Adjei, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
JCO Precision Oncology|September 27, 2021
Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous CarcinomaM Herman Chui, Jason C Chang, Yanming Zhang, et al.
ESMO Open|September 12, 2025
A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumorsA M Schram, N Takebe, A Chen, et al.
Pageof 19

Showing results (41-50 of 186) with videos related to

Sort By:
Pageof 19
JCO Precision Oncology|March 21, 2025
Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase InhibitorsMara Rao, Madeline Merrill, Megan Troxel, et al.
Disability and Health Journal|June 10, 2024
Systemic barriers hinder person-centered home and community based services (HCBS): Perspectives of service users and professionalsNiveda Tennety, Bridgette M Schram, Jacqueline Kish, et al.
British Journal of Haematology|November 6, 2015
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 yearsAlison M Schram, Paige Comstock, Meghan Campo, et al.
American Journal of Clinical Pathology|July 17, 2023
BRAF testing modalities in histiocytic disorders: Comparative analysis and proposed testing algorithmAldo A Acosta-Medina, Jithma P Abeykoon, Ronald S Go, et al.
British Journal of Cancer|November 15, 2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursAlison M Schram, Leena Gandhi, Monica M Mita, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
ESMO Open|February 22, 2025
A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumorsA M Schram, V Boni, A A Adjei, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
JCO Precision Oncology|September 27, 2021
Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous CarcinomaM Herman Chui, Jason C Chang, Yanming Zhang, et al.
ESMO Open|September 12, 2025
A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumorsA M Schram, N Takebe, A Chen, et al.
Pageof 19